Skip to content

Released Aug 6, 2019, after the close

10-Q filed Aug 6, 2019, 37 days after period end · 0001564590-19-029333

Q2 2019 · 10-Q
Revenue$2.82M+174.3% vs Q2 2018+7.0% vs Q1 2019
Net Income-$23.48MN/M vs Q2 2018N/M vs Q1 2019
EPS Diluted-$0.36N/M vs Q2 2018N/M vs Q1 2019
Operating Income-$24,084,000N/M
Operating Cash Flowderived-$20,309,000N/M
Free Cash Flowderived-$22,104,000N/M
Margins · derived
Operating margin-855.0%+1054.0 pt vs Q2 2018
Net margin-833.4%+1080.3 pt vs Q2 2018

What the release said

The release

Same quarter

MetricQ2 2019Q2 2018Q2 2017Q2 2016
Revenue$2.82M$1.03M$1.03M$1.03M
Net Income-$23.48M-$19.65M-$9.65M-$8.41M
EPS Diluted-$0.36-$0.37-$0.23-$0.29

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Fate Therapeutics Inc · CIK 1434316 · Engraved from SEC EDGAR